Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by SMARCB1 is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. Additionally we are shipping SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Proteins (20) and SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Kits (4) and many more products for this protein.
Showing 10 out of 133 products:
Human Monoclonal SMARCB1 Primary Antibody for IF, WB - ABIN968741
Bruder, Dumanski, Kedra: The mouse ortholog of the human SMARCB1 gene encodes two splice forms. in Biochemical and biophysical research communications 1999
Show all 3 references for 968741
Human Polyclonal SMARCB1 Primary Antibody for WB - ABIN2778302
Lazrek, Goffard, Schanen, Karquel, Bocket, Lion, Devaux, Hedouin, Gosset, Hober: Detection of hepatitis C virus antibodies and RNA among medicolegal autopsy cases in Northern France. in Diagnostic microbiology and infectious disease 2006
Show all 2 references for 2778302
Human Polyclonal SMARCB1 Primary Antibody for WB - ABIN658274
Bakshi, Hassan, Pratap, Lian, Montecino, van Wijnen, Stein, Imbalzano, Stein: The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes. in Journal of cellular physiology 2010
Show all 2 references for 658274
Human Polyclonal SMARCB1 Primary Antibody for IF (p), IHC (p) - ABIN762566
McAndrew, Gjidoda, Tagore, Miksanek, Floer: Chromatin Remodeler Recruitment during Macrophage Differentiation Facilitates Transcription Factor Binding to Enhancers in Mature Cells. in The Journal of biological chemistry 2016
Human Polyclonal SMARCB1 Primary Antibody for ICC, IF - ABIN4354923
Singh, Archer: Analysis of the SWI/SNF chromatin-remodeling complex during early heart development and BAF250a repression cardiac gene transcription during P19 cell differentiation. in Nucleic acids research 2014
Human Polyclonal SMARCB1 Primary Antibody for ICC, IF - ABIN252863
Young, Jacks: Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. in Proceedings of the National Academy of Sciences of the United States of America 2010
Human Monoclonal SMARCB1 Primary Antibody for WB - ABIN393962
Wu, Ho, Lin, Lin: Rhabdoid papillary meningioma: a clinicopathologic case series study. in Neuropathology : official journal of the Japanese Society of Neuropathology 2011
Cow (Bovine) Polyclonal SMARCB1 Primary Antibody for IHC, WB - ABIN2778301
Mueller, Eum, Lass, Paulus, Sarkar, Bruck, von Deimling: No evidence of hSNF5/INI1 point mutations in choroid plexus papilloma. in Neuropathology and applied neurobiology 2004
Biallelic alterations in the INI1 gene were identified in 4 of the 5 cases of atypical teratoid/rhabdoid tumors. Three of the 4 cases harbored 2 different mutations, presumably on different alleles (compound heterozygous mutations), and 1 case of which had a splice-site mutation.
The epithelioid variant of schwannoma is rare, and loss of SMARCB1/INI1 expression has been observed in a subset of cases. Our aim was to further define the clinicopathologic features and to evaluate SMARCB1/INI1 deficiency in a large cohort of 65 epithelioid schwannomas diagnosed between 2002 and 2015
SMARCB1 is required for the integrity of SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complexes.
INI1 loss occurs rarely in colorectal carcinoma, where it is associated with higher grade, larger tumor size, poorer survival, mismatch repair deficiency, and BRAFV600E mutation.
SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) complexes lacking SMARCB1 are vital determinants of drug sensitivity, not just to TOP2A (show TOP2A Antibodies)-targeted agents, but to the much broader range of cancer drugs effluxed by ABCB1 (show ABCB1 Antibodies).
SMARCB1-deficient sinonasal carcinoma represents an emerging poorly differentiated/undifferentiated sinonasal carcinoma.
Deletions in INI1 gene is associated with Small cell undifferentiated hepatoblastomas.
Our results confirm the pathogenic involvement of SMARCB1/INI1 in childhood chordoma
Rpt1 domain of INI1 may participate in ubiquitin recognition or binding with ubiquitin or ubiquitin related proteins.
Here, the authors first confirmed that SWIRM domain of BAF155 is responsible for its interaction with BAF47 and then narrowed down the SWIRM-binding region in BAF47 to the Repeat 1 (RPT1) domain.
The occurrence of intracranial rhabdoid tumours depends on control of Smarcb1 inactivation.
These results support recent findings regarding the effectivity of EGFR (show EGFR Antibodies) inhibitors in hindering the proliferation of human MRT cells and demonstrate that activation of EGFR (show EGFR Antibodies) signaling in Rhabdoid tumors is SMARCB1 dependent.
these findings uncover a novel role for Snf5 in oligodendrocyte generation and survival, and they offer evidence of the first genetically engineered mouse model for AT/RT in the CNS.
This study show here that loss of Smarcb1 and Smarca4 (show SMARCA4 Antibodies) leads to severe proliferation deficits of granule neuron precursors and a hypoplastic cerebellum.
results show that Smarcb1 is required for transcriptional activation of Igfbp7 (show IGFBP7 Antibodies) and show that re-introduction of Igfbp7 (show IGFBP7 Antibodies) alone can hinder tumor development; results define a novel mechanism for Smarcb1-mediated tumorigenesis
We find that inactivation of either Brg1 (show SMARCA4 Antibodies) or Smarcb1 leads to disruptions of specific nucleosome patterning combined with a loss of overall nucleosome occupancy at a large number of promoters, regardless of their association with CpG islands.
SNF5 is a key mediator of Hedgehog (show SHH Antibodies) signaling and that aberrant activation of GLI1 (show GLI1 Antibodies) is a previously undescribed targetable mechanism contributing to the growth of malignant rhabdoid tumor cells.
Loss of the SNF5 tumor suppressor leads to elevated expression of the Polycomb (show CBX2 Antibodies) gene EZH2 (show EZH2 Antibodies).
SNF5 knockdown inhibits p53 (show TP53 Antibodies) translation by eIF4E (show EIF4E Antibodies) and replacement of eIF4E (show EIF4E Antibodies) in SNF5 knockdown cells restores p53 (show TP53 Antibodies) expression and cell survival
The loss of this protein, a core subunit of SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies), results in highly penetrant cancer predisposition with 100% of mice developing mature CD8 (show CD8A Antibodies)(+)T cell lymphoma or rare rhabdoid tumors with a median onset of only 11 weeks.
The protein encoded by this gene is part of a complex that relieves repressive chromatin structures, allowing the transcriptional machinery to access its targets more effectively. The encoded nuclear protein may also bind to and enhance the DNA joining activity of HIV-1 integrase. This gene has been found to be a tumor suppressor, and mutations in it have been associated with malignant rhabdoid tumors. Two transcript variants encoding different isoforms have been found for this gene.
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1
, matrix metalloproteinase 11 (stromelysin 3)
, BRG1-associated factor 47
, SNF5 homolog
, integrase interactor 1 protein
, malignant rhabdoid tumor suppressor
, sucrose nonfermenting, yeast, homolog-like 1
, SWI/SNF-related matrix associated protein